CRS · Carpenter Technology Corp

Current Thesis

Carpenter Technology’s aerospace-alloy earnings story now requires a recovery above the September 4 close of $475.33 and delivery of its July 30 earnings guidance; a weekly close below $408.12 would end this recovery hypothesis. The supplied adjusted market series puts the September 18 close at $408.12, below the September 4 close of $475.33 and the previously invalidated $532 recovery threshold. The pause described in the September 6 coverage has therefore failed.

As an interpretation of that price structure, the narrative is dead — the former momentum leg remains broken as of 2026-09-18. The separate recovery hypothesis rests on management’s 2026-07-30 forecast of fiscal 2027 operating income of $850–880 million; that forecast is a company expectation, not a measured result. Company results

Bullish and bearish views on Carpenter Technology Corp

The model's bull view on Carpenter Technology Corp (CRS), in brief: Operating guidance remains the test. On 2026-07-30, management forecast first-quarter fiscal 2027 operating income of $195–200 million. Delivery within that range would supply operating evidence for the recovery case; a result below $195 million would contradict it. Filed… The bear view: The September pause has failed. The adjusted close fell below the 2026-09-04 reference of $475.33 to $408.12 on 2026-09-18. The supplied September 18 series reports a three-month decline of 30.5% and a price 34.1% below its 52-week high. Institutional evidence predates the… Both cases follow in full.

Bull Case

• Operating guidance remains the test. On 2026-07-30, management forecast first-quarter fiscal 2027 operating income of $195–200 million. Delivery within that range would supply operating evidence for the recovery case; a result below $195 million would contradict it. Filed results
• Margins provide measured operating evidence. Specialty Alloys Operations reported a record adjusted operating margin of 37.8% for the quarter ended 2026-06-30, announced on July 30. That establishes the profitability already achieved, without establishing its durability. Company results
• Repurchase authority expanded in August. The company announced an additional $1.0 billion repurchase authorization on 2026-08-12. Authorization establishes capacity for repurchases; it does not establish subsequent execution or a market price floor. Company investor relations

Bear Case

• The September pause has failed. The adjusted close fell below the 2026-09-04 reference of $475.33 to $408.12 on 2026-09-18. The supplied September 18 series reports a three-month decline of 30.5% and a price 34.1% below its 52-week high.
• Institutional evidence predates the headline. Benzinga’s 2026-09-11 report describes Third Point’s 31% reduction during the quarter ended June 30, disclosed in August. It establishes historical institutional selling, but cannot establish September selling or aggregate investor crowding. Benzinga report
• Leadership succession changed after July. The 2026 proxy states that Brian Malloy died on 2026-07-24 and Tony Thene became chairman, president and chief executive officer effective July 26. The earlier description of Malloy leading fiscal 2027 is superseded by this filing; no operating impact is established by the leadership change alone. Company proxy

Setup & Price Structure

Measured on 2026-09-18, the supplied 14-period relative strength index (RSI) was 15.8. That reading accompanies the decline; the available observations are too few to support a claim that a reversal has started. No moving-average value or trading-volume series is supplied, so neither distance from a rising average nor expanding participation can be established.

The recovery hypothesis uses the September 18 market close of $408.12 as its explicit failure boundary. That single observation does not establish a support shelf. Its price confirmation would be a weekly close above $475.33, the September 4 reference close, before a weekly close below $408.12 occurs.

Retail-facing historical-return coverage continued on 2026-09-07, following similar Benzinga items dated August 7 and August 25. These publication dates establish recurring attention; the sample is too small to establish crowded ownership or explain the decline. Benzinga news chronology

Catalyst Calendar (next 30 days)

• 2026-10-06 — Annual shareholder meeting. The company’s 2026 proxy schedules the meeting for this date. Its governance votes do not themselves resolve delivery of the operating-income forecast. Company proxy
• ~2026-10-22, estimated — First-quarter fiscal 2027 results. This falls beyond the next 30 days but is the operating test on which the recovery hypothesis turns. MarketBeat identifies the date as estimated from reporting history; the company calendar reviewed on September 20 does not announce it. The report would measure performance against the July 30 first-quarter guidance and provide any revision to the fiscal-year outlook. Estimated earnings date, company calendar

What Would Change Our Mind

Failure to preserve the September 18 reference close would reject the new recovery hypothesis: a weekly close below $408.12 is the observable price condition. The old $532 threshold has already failed and cannot serve as an upcoming test.

For this case to play out, a weekly close above the September 4 reference of $475.33 must accompany first-quarter operating income of at least $195 million and fiscal-year guidance with a lower bound of at least $850 million, before the price invalidation occurs. Those operating thresholds come from management’s 2026-07-30 outlook. A first-quarter miss or a reduction below that annual threshold would separately break the earnings premise. Filed outlook

Correlation Notes

This is a single-name recovery hypothesis. Carpenter’s investor-relations page, reviewed on 2026-09-20, identifies aerospace and defense as more than 60% of revenue, establishing an operating connection to that industry. No paired return series is supplied, so a stock-price correlation with aerospace peers, rare-earth producers or broader equity indexes cannot be stated. Company market exposure